• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Ozurdex (dexamethasone)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Ozurdex (dexamethasone)

  • Profile

Profile

Contact Information

Contact: Allergan
Website: http://www.ozurdex.com/

Currently Enrolling Trials

    Show More

    General Information

    Ozurdex is specifically indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

    Mechanism of Action

    Ozurdex is an intravitreal implant containing 0.7 mg (700 µg) dexamethasone in the Novadur solid polymer drug delivery system. Dexamethasone, a potent corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

    Side Effects

    Adverse events associated with the use of Ozurdex may include, but are not limited to, the following:

    • Intraocular pressure increased
    • Conjunctival hemorrhage
    • Eye pain
    • Conjunctival hyperemia
    • Ocular hypertension
    • Cataract
    • Vitreous detachment
    • Headache

    Dosing/Administration

    Ozurdex is supplied as a 0.7-mg implant for intravitreal injection.

    Clinical Trial Results

    FDA Approval
    The FDA approval of Ozurdex was based on the results of two multicenter, double-masked, randomized, parallel studies. Following a single injection of Ozurdex, the following clinical results for the percentage of patients with ≥ 15 letters of improvement from baseline in best-corrected visual acuity (BCVA):

    Study One (n=403)

    ·  Day 30: 20 percent for the Ozurdex arm vs. 7 percent for placebo (p<0.01)

    ·  Day 60: 29 percent vs. 10 percent (p<0.01)

    ·  Day 90: 22 percent vs.(12 percent (p<0.01)

    ·  Day 180: 19 percent vs. 18 percent (p= 0.780)

    Study Two (n=450)

    ·  Day 30: 23 percent for the Ozurdex arm vs. 8 percent for placebo (p<0.01)

    ·  Day 60: 30 percent vs. 12 percent (p<0.01)

    ·  Day 90: 21 percent vs.14 percent (p=0.039)

    ·  Day 180: 24 percent vs. 17 percent (p=0.087)

    In each individual study and in a pooled analysis, time to achieve ≥15 letters (three-line) improvement in BCVA cumulative response rate curves were significantly faster with Ozurdex compared to sham (p< 0.01). The onset of a ≥ 15 letter (three-line) improvement in BCVA with Ozurdex occurs within the first two months after implantation in approximately 20 to 30 percent of subjects. The duration of effect persists approximately one to three months after onset of this effect.

     

     

    Approval Date: 2009-06-01
    Company Name: Allergan
    Back to Listings

    Upcoming Events

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • tablet

      Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

    • Diversity-360x240.png

      Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing